Halozyme Therapeutics (HALO) Change in Inventory (2010 - 2026)
Halozyme Therapeutics (HALO) posted quarterly Change in Inventory of -$27.4 million for Q1 2026, down 4772.18% year-over-year from $586000.0 in Q1 2025, and down 45.78% quarter-over-quarter from -$18.8 million in Q4 2025.
Halozyme Therapeutics (HALO) Change in Inventory (2010 - 2026) Analysis & Trends
Halozyme Therapeutics (HALO) has reported Change in Inventory for 17 consecutive years, with -$27.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Inventory fell 4772.18% year-over-year to -$27.4 million; the TTM figure through Mar 2026 stood at -$30.5 million (down 210.04% YoY), while the FY2025 annual figure was -$2.6 million, down 103.79% from the prior year.
- Change in Inventory slipped to -$27.4 million in Q1 2026 per HALO's latest filing, from -$18.8 million in the prior quarter.
- Across five years, Change in Inventory topped out at $40.2 million in Q1 2024 and bottomed at -$27.4 million in Q1 2026.
- Historically, Change in Inventory has averaged $4.8 million across 5 years, with a median of $2.9 million in 2022.
- Annual changes were most pronounced in 2022 — Change in Inventory surged 17717.44% — and 2026, when it slumped 4772.18%.
- Halozyme Therapeutics' Change in Inventory stood at $2.9 million in 2022, then plunged by 149.88% to -$1.5 million in 2023, then soared by 625.94% to $7.7 million in 2024, then sank by 343.09% to -$18.8 million in 2025, then slumped by 45.78% to -$27.4 million in 2026.
- Business Quant data shows HALO's Change in Inventory at -$27.4 million in Q1 2026, -$18.8 million in Q4 2025, and $1.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Inventory (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 28.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 47.15 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,188.52 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -280,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 12.97 Mn |
| 10 | Halozyme Therapeutics | 11.25 Bn | 11.02 Bn | 401.83 Mn | -18.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -18.33 Mn |
| Jun 30, 2026 | -18.33 Mn |
| Mar 31, 2026 | -27.38 Mn |
| Mar 31, 2026 | -27.38 Mn |
| Dec 31, 2025 | -18.78 Mn |
| Dec 31, 2025 | -18.78 Mn |
| Sep 30, 2025 | 1.10 Mn |
| Sep 30, 2025 | 1.10 Mn |
| Jun 30, 2025 | 14.54 Mn |
| Jun 30, 2025 | 14.54 Mn |
| Mar 31, 2025 | 586,000.00 |
| Mar 31, 2025 | 586,000.00 |
| Dec 31, 2024 | 7.73 Mn |
| Dec 31, 2024 | 7.73 Mn |
| Sep 30, 2024 | -1.98 Mn |
| Sep 30, 2024 | -1.98 Mn |
| Jun 30, 2024 | 21.40 Mn |
| Jun 30, 2024 | 21.40 Mn |
| Mar 31, 2024 | 40.23 Mn |
| Mar 31, 2024 | 40.23 Mn |